lansoprazole has been researched along with Encapsulating Peritoneal Sclerosis in 1 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kunitatsu, K | 1 |
| Yamamoto, Y | 1 |
| Nasu, S | 1 |
| Taniji, A | 1 |
| Kawashima, S | 1 |
| Yamagishi, N | 1 |
| Ito, T | 1 |
| Inoue, S | 1 |
| Kanai, Y | 1 |
1 other study available for lansoprazole and Encapsulating Peritoneal Sclerosis
| Article | Year |
|---|---|
Novel Peritoneal Sclerosis Rat Model Developed by Administration of Bleomycin and Lansoprazole.
Topics: Animals; Bleomycin; Epithelial Cells; Lansoprazole; Male; Peritoneal Fibrosis; Peritoneum; Rats; Rat | 2023 |